
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 17, 2018

HARVARD BIOSCIENCE, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-33957
(Commission File Number)

04-3306140
(I.R.S. Employer Identification Number)

84 October Hill Road, Holliston, MA 01746
(Address of Principal Executive Offices) (Zip Code)

(508) 893-8999
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Financial Officer

On August 17, 2018, Robert E. Gagnon submitted his resignation from all positions held with Harvard Bioscience, Inc. (the “Company”), including his position as Chief Financial Officer (“CFO”), such resignation to be effective as of August 31, 2018. Mr. Gagnon did not resign for any reasons related to the Company’s accounting practices or financial statements.

A copy of the press release issued by the Company to announce the resignation of Mr. Gagnon is included as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

**Exhibit
Number Title**

99.1 [Press Release issued by Harvard Bioscience, Inc. on August 22, 2018.](#)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HARVARD BIOSCIENCE, INC.

Date: August 22, 2018

By: /s/ JEFFREY A. DUCHEMIN
Jeffrey A. Duchemin
Chief Executive Officer

INDEX TO EXHIBITS

**Exhibit
Number** **Description of Exhibit**

99.1 [Press Release issued by Harvard Bioscience, Inc. on August 22, 2018.](#)

Harvard Bioscience Announces Management Change

CFO Resigns to Pursue New Opportunity

HOLLISTON, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today announced the resignation of Robert E. Gagnon, Chief Financial Officer, effective August 31, 2018. The Company has initiated a search for its next chief financial officer.

“On behalf of the entire company, I want to thank Rob for his significant contributions during his tenure at Harvard Bioscience,” said Jeffrey A. Duchemin, President and Chief Executive Officer. “His expertise in global finance, operations and acquisitions was instrumental in transforming our company into a thriving and growing global enterprise. We wish him the very best.”

“Harvard Bioscience has an excellent management team, strong business model, outstanding employees and has been executing on all of its objectives in the first half of 2018. This decision was a very difficult one for me to make,” said Rob Gagnon. “I wish the best for my Harvard Bioscience colleagues.”

Today’s news was not the result of any matters which, to the Company’s knowledge, would have an adverse impact on the integrity of the Company’s financial statement or the results of operations.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.

CONTACT:

Corey Manchester
Vice President, Corporate Controller

Tel: 508 893 8999
Fax: 508 429 8478